The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease
The DOI matches its Crossref record.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) and its advanced form non-alcoholic steatohepatitis (NASH) are the most common causes of elevated liver enzymes in the general population. NASH, and to a lesser extent NAFLD have been associated with increased liver-related, cardiovascular disease (CVD), and allcause mortality. No effective treatment is widely acceptable. Objective: The purpose of this review is to summarize available data on the impact of statins on NAFLD and NASH. Method: A comprehensive review of the literature was performed to identify studies assessing the effect of statin use in NAFLD/NASH. Results: Recent reports have shown that the use of statins in patients with elevated plasma aminotransferases may be beneficial. Post hoc data from three large prospective randomized clinical trials (n>11, 000) suggest that specific statins (mainly atorvastatin) ameliorate NAFLD/NASH and reduce CVD events twice as much as in those with normal liver function. Several biopsy studies have found that rosuvastatin use is related with significant histological ameliorating effects in the setting of NASH. Statin treatment may also protect from hepatocellular carcinoma (HCC) related to NAFLD/NASH. Conclusion: Since NAFLD/NASH patients have high CVD risk, they will probably require a statin. Thus, why not select a specific statins (atorvastatin or rosuvastatin, both generic now) that offer a substantial liver- and CVDrelated adverse event reduction? The administration of statins in these patients is as safe as in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
Tang, Y., Huang, J., Zhang, W. Y., Qin, S., Yang, Y. X., Ren, H., Yang, Q.-B., & Hu, H. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819878046 · Cited by 85
“1 17 (3) versus 13 (6); 14 (3) versus 16 (3) 20 (19); 17 (19) DFI, WHR, weight, BMI, TC, LDL-C, HDL-C, TG, Glu, insulin, ALT, AST, ALP, γ-GT, ALB, HOMA-IR”
Zhang, J., Fu, S., Liu, D., Wang, Y., & Tan, Y. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002517 · Cited by 27
Ren, Q., Tan, Y., Zhang, G., Dai, Y., Yang, L., Wu, Y., He, H., & Chen, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70021 · Cited by 9
Metadata
- Authors
- Doumas, M., Imprialos, K., Dimakopoulou, A., Stavropoulos, K., Binas, A., & Athyros, V. G.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2019-02-27
- Volume
- 24
- Issue
- 38
- Pages
- 4587-4592
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2910054046
- Cited by
- 70
- References
- 0
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. https://app.cochat.ai/papers/10.2174/1381612825666190117114305
- The paper
- Doumas, M., Imprialos, K., Dimakopoulou, A., Stavropoulos, K., Binas, A., & Athyros, V. G. (2019). The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. Current Pharmaceutical Design. https://doi.org/10.2174/1381612825666190117114305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.